Rhythm Pharmaceuticals (NASDAQ:RYTM) reported better-than-expected first-quarter financial results on Tuesday.
Rhythm Pharmaceuticals posted quarterly losses of 83 cents per share, beating market estimates of losses of 84 cents per share. The company’s sales came in at $60.112 million surpassing market estimates of $55.776 million.
“The U.S and European approvals of IMCIVREE mark a transformational milestone for patients with acquired hypothalamic obesity (HO) who, until now, had no approved therapies for this devastating disease,” said David Meeker, M.D., Chairman, Chief Executive Officer and President of Rhythm Pharmaceuticals. “The U.S. launch is off to a strong start, as patient demand and physician engagement in this early stage of the launch reinforce the significant unmet need and long-term opportunity …